CyDex Pharmaceuticals to Present at Cowen and Company's 29th Annual Health Care Conference.LENEXA, Kan. -- CyDex Pharmaceuticals, Inc. today announced CyDex President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Theron Odlaug will be presenting at Cowen and Company's 29th Annual Health Care Conference on Thursday, March 12, 2009 at 9:00 a.m. at the Boston Marriott Copley Place Copley Place is an enclosed shopping mall located in the Back Bay section of Boston, Massachusetts. It is part of a complex that includes office buildings, two hotels, and a parking garage. . "We look forward to speaking with the investment community about CyDex's progress in developing both partner and retained product pipelines for our Captisol([R]) technology," said Odlaug. "Major pharmaceutical companies continue to license our Captisol technology platform to improve solubility, stability, bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. , safety and/or dosing of a number of active pharmaceutical ingredients. We also look forward to developing and marketing our own Captisol-Enabled([R]) line of specialty pharmaceutical injectable products that target unmet needs in intravenous therapy." About CyDex Pharmaceuticals CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol([R]) technology. CyDex is developing its own pipeline of products using its enabling technology solutions and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. The company maintains patents in the U.S. and worldwide for its Captisol and cyclodextrin technologies, and a comprehensive FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. drug master file Drug Master File or DMF is a document prepared by a manufacturer in the pharmaceutical industry and submitted solely at his discretion to the Food and Drug Administration (FDA). There is no requirement by law or FDA regulation to present a DMF. for client use. For additional information on business development opportunities, please contact Ralph Johnston at rjohnston@cydexpharma.com or 913.685.8850. CyDex is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion